Sangamo Therapeutics experienced a significant surge in its stock price, jumping by as much as 53%, after the U.S. Food and Drug Administration (FDA) indicated support for an accelerated approval pathway for its gene therapy drug, isaralgagene civaparvovec (ST-920), designed to treat Fabry disease. The FDA’s guidance permits Sangamo to proceed with a streamlined clinical […]
Sangamo Therapeutics, a genomic medicine company, has entered an evaluation and option agreement with Prevail Therapeutics, an Eli Lilly subsidiary, for novel engineered capsids. The deal allows Prevail Therapeutics to evaluate Sangamo Therapeutics’ proprietary adeno-associated virus (AAV) capsids for potential use in various neurological targets. The capsids, produced through Sangamo Therapeutics’ AAV capsid engineering platform […]
